Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 8, 2014

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Metastatic Prostate CancerPain
Interventions
DRUG

Radium-223

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

New York Presbyterian Hospital-Weill Medical College of Cornell University, New York

27514

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

University of North Carolina

OTHER

collaborator

New York Presbyterian Hospital

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02278055 - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter